Section
This study reveals coordinated cellular programs underlying response and resistance to neoadjuvant PD-L1 blockade in ESCC, highlighting potential combinatorial immunotherapy targets for personalized treatment strategies.
T-cell lymphomas after CAR T-cell therapy are exceedingly rare but significant. This article reviews incidence, mechanisms, diagnostic challenges, and clinical implications to guide vigilance without overshadowing CAR T-cell therapy’s
PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.
The phase 3 SYMPATICO trial demonstrated that first-line combination therapy with ibrutinib and venetoclax yields high complete response rates and durable remissions in patients ≥65 years or with TP53 mutations suffering from nonblastoid ma
This review synthesizes current evidence comparing patient-perceived quality of shared decision-making (SDM) for lung cancer screening (LCS) delivered via telehealth versus in-person encounters, highlighting comparable outcomes and implicat
This multicenter study evaluates how the surgical learning phase impacts major complications and oncological quality in robotic left-sided pancreatectomy, demonstrating safe adoption with consistent morbidity and highlighting the need for o
A randomized clinical trial demonstrated that the 5x-multiplier algorithm significantly reduces opioid prescriptions at discharge without increasing consumption, refill rates, or patient dissatisfaction after major abdominal cancer surgery
This study compares radiographic versus pathology-integrated response metrics to identify optimal surgical timing after neoadjuvant imatinib treatment in KIT exon 11-mutant gastrointestinal stromal tumors (GIST). Pathology measures indicate
A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients
This longitudinal study reveals that gut microbiome remodeling during immune checkpoint inhibitor therapy in advanced liver cancer patients predicts clinical benefit, improving biomarker accuracy and survival stratification.
A multicenter German registry study comparing carboplatin/paclitaxel to other chemotherapy regimens in anaplastic thyroid cancer found no survival advantage, highlighting the importance of molecular diagnostics and multimodal treatment appr
Left ventricular pressure overload induces metabolic vulnerability that heightens susceptibility to anthracycline cardiotoxicity, revealing a critical need for targeted preventive strategies in patients with hypertension or valvular disease
PDS0101 combined with pembrolizumab demonstrated encouraging efficacy and safety in immune checkpoint inhibitor-naive HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma, supporting further first-line evaluation.
A meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup’s treatment.
This article explores how PD-L1 and PD-L2 differentially regulate immune and lineage-specific programs in primary mediastinal large B-cell lymphoma, providing insights for tailored immunotherapy.
LINC01521 is significantly upregulated in papillary thyroid carcinoma, promoting tumor progression by targeting miR-4319 and inhibiting cuproptosis, thereby serving as an independent prognostic marker for adverse clinical outcomes.
Breast cancer independently increases atrial fibrillation risk via tumour-secreted ADAM10, which induces atrial fibrosis through the Ephrin B2 signaling pathway, offering a potential new therapeutic target.
Early measurable residual disease (MRD) negativity and timing of relapse are crucial for risk stratification in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamic
This pooled analysis evaluates the safety and effectiveness of the Colovac Anastomosis Protection Device compared to standard diverting loop ileostomy following low anterior resection for rectal cancer, showing comparable major complication
This study highlights how HPV and TP53 molecular subtyping in stage I vulvar squamous cell carcinoma delineates survival outcomes and recurrence risks, supporting its role in personalized management strategies.
